New and notable appointments at: Dubit, DCC Energy, Achilles Therapeutics and Wilson Hartnell

Pictured: Sarah O’Connor, Deputy Chief Executive, Wilson Hartnell

This week saw New and notable appointments at: Dubit, DCC Energy, Achilles Therapeutics and Wilson Hartnell

Pictured: Paul Bone, Finance Director, Dubit

Paul Bone, Finance Director
Dubit

Dubit has made its second marquee signing in two weeks, announcing the hire of its new Finance Director (FD), Paul Bone from Chelsea Digital Ventures, a tech-focused spin-out of Chelsea Football Club. Bone joins just a week after the hire of former VP Global Head of Music at Roblox, Jonathan Vlassopulos.

Prior to his time at Chelsea Digital Ventures, Bone held C-suite finance roles at companies including mobile advertising platform, Axonix (now owned by Emodo), South Korean video games developer and publisher, NCsoft, and social game business We R Interactive. Bone’s director-level career spans more than 15 years and he will now bring his extensive experience and expertise to bear at Dubit.

Dr. Fabian Ziegler, CEO
DCC Energy

DCC plc, has announced the appointment of Dr. Fabian Ziegler as Chief Executive Officer of DCC Energy. Fabian will commence the role on 1 November 2022.

Fabian has extensive senior leadership experience in the energy sector having held various senior management roles in Shell plc during his 26-year career. He is currently Country Chair of Shell Germany and Chair of the Management Board with responsibility for Shell’s businesses (upstream, downstream, power and renewables) in the DACH region.

Commenting on the appointment, Donal Murphy, Chief Executive, said:“We conducted an extensive global search to find the best candidate to lead DCC Energy as it embarks on its next phase of growth and development. Fabian is an excellent addition to our senior management team in DCC. His track record of success, his extensive experience in the energy industry and in energy transition and his significant experience in leading large organisations leave him ideally placed to lead DCC Energy”.

James Taylor, Cassian Yee Chief Business Officer, Scientific Advisory Board
Achilles Therapeutics

Achilles Therapeutics has announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.

Mr. Taylor brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals with Genentech, Takeda, AbbVie, GSK, Verily, Aditum and Biohaven Pharmaceuticals. Prior to this, James was a senior director at GSK where he led deals with GlycoVaxyn, Novartis, Pfizer, Biological E and consulted for Galvani Bioelectronics, the GSK/Google joint venture. He has held executive management roles at AstraZeneca, Summit Therapeutics and Cellzome.

The Company has also expanded its Scientific Advisory Board with the addition of Cassian Yee, MD. Dr. Yee is a professor in the department of melanoma medical oncology and the department of immunology at The University of Texas MD Anderson Cancer Center, as well as director of the solid tumor cell therapy program at MD Anderson. He is a highly regarded immuno-oncology leader, and notable pioneer in the field of adoptive cellular therapy.

Sarah O’Connor, Deputy Chief Executive
Wilson Hartnell

Wilson Hartnell has announced the appointment of Sarah O’ Connor to the position of Deputy Chief Executive. Ms. O’Connor joined Wilson Hartnell as a Director of the Company and Head of its Sports Marketing business over six years ago and since then she has played a significant role in the growth and development of the company, leading the team to multi-award-winning work both locally and internationally.

Sharon Murphy, Chief Executive, Wilson Hartnell said, “Sarah’s appointment comes on the back of a period of very strong growth for the company. She has a rare mix of skills and experience, which will undoubtedly serve the company and our clients very well into the future. Sarah’s strategic ability is second-to-none and she brings a well-rounded perspective to all her work. Apart from her abundance of skills, she is a fantastic colleague that we are privileged to work with. I am looking forward to continuing to work with Sarah in her new role and wish her every success”.

Sarah O’ Connor commented, “Having been with Wilson Hartnell for over six years, I am more convinced than ever that good communication lies at the heart of achieving any ambition. At Wilson Hartnell, we aim to inspire ourselves and our clients to positively impact the world”.